http://exhibits.library.stonybrook.edu/mfp/files/original/7ffd0b9add6c03c7f72229c3d5d42620.pdf 3a01d918c75a9925c6919e12548d4818 PDF Text Text v‘ ww—w: I‘TJ'AW': rum ww , w’wr- ~— . _ m‘Ev’InK-K’u‘v—J—wr'nv wwwt m--. ‘kuwi—u— —-mu~.mv—xn~ October 8, 1969 Dr. Wilma Harrison Geigy Pharmaceuticals Ardsley, New York Dear Wilma, Enclosed is our interim report and revised protocol in our studies of GP-41299. Pages 1-8 are the same as the copies which you have. I have revised the clinical trial sections, following your suggestions and after discussing the possibilities with We do have a number of patients who have been my associaties. maintained on either chlordiazepoxide or doxepin for many months, and also some schizoPhrenics who have been maintained on phenothiazines. These patients can be placed on placebo. In the event that symptoms recur, we will be able to begin with GP-41299. We will have to determine the dosage first and if an effective range is observed, I would then plan to treat alternate patients with chlordiazepoxide or GP-41299. Concurrently, I plan to select a few patients admitted for severe anxiety or schizophrenia to our in—patient beds and begin Open clinical trial. In these the possibility that they are resistant will remain. laboratory data will be insured in the in—patients do our best in the out-patients. You are aware that it is often difficult to obtain the cooperation of out— patients for laboratory studies. and we The will Part two of the EEG trial (GP vs. placebo) will begin within the next few weeks. The clinical studies can begin early in November and for this I request a supply of 25 mg capsules of GP-41299. If available, 1000. It would be helpful to have 200 additional placebo capsules. nr' Hert;2ou -3- ”rm-mun».— ww‘wa- M-r"~""" w. w—,, wann— �-2* so paws 300 sqqxtrousj bzucspo cabanrea' 0:. Harrison ‘mmmao:%wnw nnmmchWWr Igunnwvrmw Lsdnca; s tabbyk Ocazx tn ”agonpox avg go: 3px: 32 m8 a; 1 ayspzn spa Box: 39» nocxa' 3pc cxyngcsx assay a can pogyn his: :80 0% cps 55c £319! (05 AI' brsccpo) MIII 908:0 buxruuca go: {spozutoxl a:nq;ea' spa: It {a ogcau nggycnxs co opziyu ape coobaxsc399 0; on:tug no my}: qo on: pea; In spa unsubsszeu52° Ann 916 auras Lpo choxssoxk gate «313 p0 Inaneq 3n 5pc In-bscyoucaA xsazatcfis 3111 Lemuru’ 938;” ofisn_c1;u;c21 £318]' In cyeae (no boazrpqrqck :ps; suck go; asaeaa anxxecx 01 acpysobpzcurs so on; :u—bsc;cnc page an caucnxstusxx' 1 bran so waxes; a gen barycuga squcccq was * » 53$?3353 M19? GPIOEqi'33501199 0‘ 65*31533' an eggpetqao’33380 I? opzszaeq 1 nonxq cyan bxan to 5x93: Cb 11333 $0 “III PBAO £0 €95313139 t?“ $03936 Elbifi “HQ IE 1n :pe ensue cpt; akwhsoma Lacnx‘ no 311] p6 SPIG so pefixn ngcp an bpeuecptsxzaca' lpeae bstycuca can pa bysceq on bxscopo' woucpa‘ an ciao acme acpyxobpnoqrca npo pane pcgn msgucsyucq wszussxucq on aquez cpyonqxsxebOXch oz qoxsbzu £01 wank wk uaaocttszca' go go paAe s unwpe; a; bItIGH$3 Ape gene poem -kon1 25880251033 auq 8££¢1 qyacnzayufl spa boeaqurysgoa nycp I psmevtsaxaoq cps CI;H;CsI tats} aoecxouz‘ £0110n3u8 Sltfihfltt‘ spycp Lea ptAO' on: aanzea o; eb~¢xsaa' 598:: 1-9 '13 spa tune 32 :pe c0516: Eucjoaoq 13 on: 13:3L1u 3550;; anq Lsayaeq bxosocox In 9981 Mrjms' vzqezeh‘ men 301; eogsx bpszmieoncycuxa 01’ at!!! H93£1303 O€£°P°1 9' 1898 �v” wwwww .- ——-r.»- m," vac—y"-W-w—w—-nmm~mm—mm‘wflw—nmwn - m. m‘watn v . - vw "a." “1,, w- "(WW‘ 7 W." v A w.,ww_—..v.m.—— Dr. Harrison ~2- October 8, 1969 WWm— Ame. While I would like to suggest that equivalent capsules of chlordiazepoxide each containing 25 mg, I am not sure that this is the best strategy. If it turns out that a clinical effective dosage of GP 41299 is much higher than 150 mg per day, then a comparison with 25 mg chlordiazepoxide would have a limitation. Either the capsules could be made up now or we might wait until we have some data to permit a better judgment. If this preliminary protocol is satisfactory, prepare a supplementary budget My request. best regards. Sincerely yours, Max Fink, M.D. Professor of Psychiatry Mszp «n “www.- ~—r Fwy-ww— .7 ,4, r-«s- rm~rm“ “MT "Ir . Wm.“ wvw—‘w *7 . I will � Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Correspondence Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Correspondence to: Harrison, Wilma Type The nature or genre of the resource Text Identifier An unambiguous reference to the resource within a given context mfp-05-00-023-5-480 Date A point or period of time associated with an event in the lifecycle of the resource 1969 Creator An entity primarily responsible for making the resource <a title="Fink, Max, 1923-" href="http://id.loc.gov/authorities/names/n79039548" target="_blank">Fink, Max, 1923-</a> Subject The topic of the resource Correspondence -- Correspondence Relation A related resource The Max Fink Collection Description An account of the resource Rights Information about rights held in and over the resource <a title="IN COPYRIGHT - EDUCATIONAL USE PERMITTED" href="http://rightsstatements.org/vocab/InC-EDU/1.0/" target="_blank">IN COPYRIGHT - EDUCATIONAL USE PERMITTED</a> Source A related resource from which the described resource is derived Special Collections and University Archives, University Libraries. Stony Brook University Libraries (State University of New York). Language A language of the resource en-US Format The file format, physical medium, or dimensions of the resource application/pdf Publisher An entity responsible for making the resource available Contributor An entity responsible for making contributions to the resource Correspondence